New Generation Cell Therapy:
Bioartificial Pancreas to Cure Type 1 Diabetes

Why needed?

Forty million individuals worldwide suffer from type 1 diabetes. This disease is managed by insulin therapy in a vast majority of patients because of the limited accessibility of beta cell replacement therapies.

There is an urgent need for the development of a beta cell replacement therapy that will be available to larger numbers of type 1 diabetic patients.

Our solution​

The VANGUARD project aims to generate a vascularized and immune-protected bioartificial pancreas that can be transplanted into non-immuno-suppressed patients by combining advanced tissue engineering strategies.

This approach will yield a cell therapy in the form of an Advanced Therapy Medicinal Product (ATMP), which can significantly improve treatment of type 1 diabetes.

Project overview

  • Consortium

    9 partners from 5 countries

  • Budget

    € 6.8 million

  • Duration

    01.01.2020 – 31.12.2024


New VANGUARD infographic available

To introduce the VANGUARD project in easier to understand terms we have developed an infographic to explain the complex research happening in VANGUARD

New publications from the UNIGE group

VANGUARD is generating its first scientific outcomes, as seven works from the UNIGE group have recently been accepted and published in various journals such as

VANGUARD featured in the Horizon EU magazine

Horizon, the official magazine for EU-funded research and innovation projects, has published an article about emerging treatments against diabetes. It includes an interview of the